Shares

15 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2021

May 12, 2021

SELL
$4.86 - $13.07 $1.26 Million - $3.39 Million
-259,245 Closed
0 $0
Q4 2020

Feb 16, 2021

SELL
$9.48 - $12.84 $264,966 - $358,878
-27,950 Reduced 9.73%
259,245 $3.28 Million
Q3 2020

Nov 16, 2020

SELL
$8.67 - $10.82 $177,188 - $221,128
-20,437 Reduced 6.64%
287,195 $2.82 Million
Q2 2020

Aug 12, 2020

SELL
$7.8 - $11.52 $136,975 - $202,302
-17,561 Reduced 5.4%
307,632 $3.06 Million
Q1 2020

May 12, 2020

SELL
$5.98 - $13.09 $254,748 - $557,634
-42,600 Reduced 11.58%
325,193 $2.87 Million
Q4 2019

Feb 11, 2020

SELL
$5.71 - $9.22 $75,120 - $121,298
-13,156 Reduced 3.45%
367,793 $3.39 Million
Q3 2019

Nov 13, 2019

BUY
$5.88 - $12.35 $168,232 - $353,345
28,611 Added 8.12%
380,949 $2.24 Million
Q2 2019

Aug 08, 2019

BUY
$9.44 - $13.12 $2.09 Million - $2.91 Million
221,512 Added 169.32%
352,338 $0
Q1 2019

May 15, 2019

BUY
$12.07 - $17.54 $593,964 - $863,143
49,210 Added 60.29%
130,826 $0
Q4 2018

Feb 07, 2019

BUY
$11.25 - $16.17 $18,112 - $26,033
1,610 Added 2.01%
81,616 $1.02 Million
Q3 2018

Nov 07, 2018

SELL
$12.82 - $17.88 $36,613 - $51,065
-2,856 Reduced 3.45%
80,006 $0
Q2 2018

Aug 13, 2018

BUY
$16.83 - $21.66 $150,763 - $194,030
8,958 Added 12.12%
82,862 $0
Q1 2018

May 04, 2018

BUY
$19.24 - $28.03 $432,149 - $629,581
22,461 Added 43.66%
73,904 $0
Q4 2017

Feb 13, 2018

SELL
$13.96 - $29.05 $187,999 - $391,216
-13,467 Reduced 20.75%
51,443 $1.33 Million
Q3 2017

Nov 02, 2017

BUY
$13.91 - $15.31 $902,898 - $993,772
64,910
64,910 $958,000

Others Institutions Holding CNCE

# of Institutions
1
Shares Held
0
Call Options Held
0
Put Options Held
0

About CONCERT PHARMACEUTICALS, INC.


  • Ticker CNCE
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 47,934,600
  • Description
  • Concert Pharmaceuticals, Inc. operates as a clinical stage biopharmaceutical company that develops novel small molecule drugs for the treatment of autoimmune diseases. The company's lead product candidate is CTP-543, which is in Phase III clinical trial for the treatment of alopecia areata, a serious autoimmune dermatological condition. It has s...
More about CNCE
Track This Portfolio

Track Prudential Financial Inc Portfolio

Follow Prudential Financial Inc and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Prudential Financial Inc, based on Form 13F filings with the SEC.

News

Stay updated on Prudential Financial Inc with notifications on news.